These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11948106)

  • 1. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.
    Corey E; Quinn JE; Emond MJ; Buhler KR; Brown LG; Vessella RL
    Clin Cancer Res; 2002 Apr; 8(4):1003-7. PubMed ID: 11948106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LuCaP 35: a new model of prostate cancer progression to androgen independence.
    Corey E; Quinn JE; Buhler KR; Nelson PS; Macoska JA; True LD; Vessella RL
    Prostate; 2003 Jun; 55(4):239-46. PubMed ID: 12712403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells.
    Gery S; Sawyers CL; Agus DB; Said JW; Koeffler HP
    Oncogene; 2002 Jul; 21(31):4739-46. PubMed ID: 12101412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Rocchi P; Muracciole X; Fina F; Mulholland DJ; Karsenty G; Palmari J; Ouafik L; Bladou F; Martin PM
    Oncogene; 2004 Dec; 23(56):9111-9. PubMed ID: 15489889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
    Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
    Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
    Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
    Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CL1-GFP: an androgen independent metastatic tumor model for prostate cancer.
    Patel BJ; Pantuck AJ; Zisman A; Tsui KH; Paik SH; Caliliw R; Sheriff S; Wu L; deKernion JB; Tso CL; Belldegrun AS
    J Urol; 2000 Oct; 164(4):1420-5. PubMed ID: 10992426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.
    Freedland SJ; Pantuck AJ; Paik SH; Zisman A; Graeber TG; Eisenberg D; McBride WH; Nguyen D; Tso CL; Belldegrun AS
    Prostate; 2003 Jun; 55(4):299-307. PubMed ID: 12712409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of Maspin expression by androgen ablation.
    Zou Z; Zhang W; Young D; Gleave MG; Rennie P; Connell T; Connelly R; Moul J; Srivastava S; Sesterhenn I
    Clin Cancer Res; 2002 May; 8(5):1172-7. PubMed ID: 12006534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.
    Kyprianou N; English HF; Isaacs JT
    Cancer Res; 1990 Jun; 50(12):3748-53. PubMed ID: 2340521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.